The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Open accessAbstract
Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient. This heterogeneity in treatment response could result from genetic modifiers that regulate the degree to which tumour cells are dependent on mutant EGFR. Through a pooled RNA interference screen, we show that knockdown of FAS and several components of the NF-κB pathway specifically enhanced cell death induced by the EGFR TKI erlotinib in EGFR-mutant lung cancer cells. Activation of NF-κB through overexpression of c-FLIP or IKK (also known as CFLAR and IKBKB, respectively), or silencing of IκB (also known as NFKBIA), rescued EGFR-mutant lung cancer cells from EGFR TKI treatment. Genetic or pharmacologic inhibition of NF-κB enhanced erlotinib-induced apoptosis in erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models. Increased expression of the NF-κB inhibitor IκB predicted for improved response and survival in EGFR-mutant lung cancer patients treated with EGFR TKI. These data identify NF-κB as a potential companion drug target, together with EGFR, in EGFR-mutant lung cancers and provide insight into the mechanisms by which tumour cells escape from oncogene dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In erlotinib-sensitive and erlotinib-resistant EGFR-mutant lung cancer models, genetic or pharmacologic inhibition of NF-κB increased erlotinib-induced apoptosis [114].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Self-citationPreexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
Luo, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26322 · Cited by 898
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma
Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., & Jacks, T. (2009) · Nature · doi:10.1038/nature08462 · Cited by 514
Cited by
Sorted by citations
Items 101–200 of 400
Zhang, J., Zhang, Y., Wu, W., Wang, F., Liu, X., Shui, G., & Nie, C. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.559 · Cited by 73
Lee, P., Fang, Y., Yamaguchi, H., Wang, W., Chen, T.-C., Hong, X., Ke, B., Xia, W., Wei, Y., Zha, Z., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.007 · Cited by 71
Huang, L. F., Brunell, D. J., STEPHAN, C. C., Mancuso, J. J., Yu, X., He, B., Thompson, T. C., Zinner, R., Kim, J., Davies, P. J., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz109 · Cited by 72
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop
Shi, L., Wang, Y., Lü, Z., Zhang, H., Zhuang, N., Wang, B., Song, Z., Chen, G., Huang, C., Xu, D., et al. (2016) · Oncogene · doi:10.1038/onc.2016.332 · Cited by 71
Kharbanda, A., Rajabi, H. N., Jin, C., Tchaicha, J. H., Kikuchi, E., Wong, K., & Kufe, D. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3168 · Cited by 70
EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy
Zahonero, C., & Sánchez‐Gómez, P. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1608-1 · Cited by 71
Ma, X., Lv, X., & Zhang, J. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.049 · Cited by 71
Jiang, X.-M., Xu, Y.-L., Yuan, L.-W., Zhang, L., Huang, M.-Y., Ye, Z.-H., Su, M., Chen, X.-P., Zhu, H., Ye, R. D., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0457-8 · Cited by 71
Ravi, J., Sneh, A., Shilo, K., Nasser, M. W., & Ganju, R. K. (2014) · Oncotarget · doi:10.18632/oncotarget.1723 · Cited by 69
Dermawan, J. K. T., Gurova, K. V., Pink, J. J., Dowlati, A., De, S., Narla, G., Sharma, N., & Stark, G. R. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0013 · Cited by 68
Okamoto, K., Okamoto, I., Hatashita, E., Kuwata, K., Yamaguchi, H., Kita, A., Yamanaka, K., Ono, M., & Nakagawa, K. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0638 · Cited by 68
CD95 in cancer: tool or target?
Martín-Villalba, A., Llorens-Bobadilla, E., & Wollny, D. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.002 · Cited by 70
Inoue, A., Yoshida, K., Morita, S., Imamura, F., Seto, T., Okamoto, I., Nakagawa, K., Yamamoto, N., Muto, S., & Fukuoka, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw014 · Cited by 69
The CD95/CD95L signaling pathway: A role in carcinogenesis
Fouqué, A., Debure, L., & Legembre, P. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.007 · Cited by 72
TRAF2 is an NF-κB-activating oncogene in epithelial cancers
Shen, R. R., Zhou, A. Y., Kim, E., O’Connell, J. T., Hägerstrand, D., Beroukhim, R., & Hahn, W. C. (2013) · Oncogene · doi:10.1038/onc.2013.543 · Cited by 70
Mechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67
Self-citationKhadra, N., Bresson‐Bepoldin, L., Penna, A., Chaigne-Delalande, B., Ségui, B., Levade, T., Vacher, A.-M., Reiffers, J. J., Ducret, T., Moreau, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116946108 · Cited by 65
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64
Ray, K., Újvári, B., Ramana, V., & Donald, J. A. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.002 · Cited by 64
Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Fernando, R. I., Hamilton, D. H., Dominguez, C. L., David, J. M., McCampbell, K. K., & Palena, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9662 · Cited by 62
Chen, H., Wang, J., Feng, X., Zhu, M., Hoffmann, S., Hsu, A., Qian, K., Huang, D., Zhao, F. H., Liu, W., et al. (2019) · Chemical Science · doi:10.1039/c9sc01410a · Cited by 62
SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR
Zhao, L., Qiu, T. H., Jiang, D., Xu, H., Zou, L., Yang, Q., Chen, C., & Jiao, B. (2020) · Advanced Science · doi:10.1002/advs.201903700 · Cited by 63
Lou, W., Chen, Y., Zhu, K., Deng, H., Wu, T., & Wang, J. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00271 · Cited by 62
The Fire Within: NF-κB Involvement in Non–Small Cell Lung Cancer
Dimitrakopoulos, F.-I. D., Kottorou, A. E., Kalofonou, M., & Kalofonos, H. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3578 · Cited by 61
Thu, K. L., Pikor, L. A., Chari, R., Wilson, I. M., MacAulay, C. E., English, J. C., Tsao, M., Gazdar, A. F., Lam, S. C., Lam, W. L., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182289479 · Cited by 60
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Workman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 60
Yang, G., Han, D., Chen, X., Zhang, D., Wang, L., Chen, S., Zhang, W., Li, C., Chen, X., Liu, H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not307 · Cited by 58
Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
Zeng, H., Castillo-Cabrera, J., Manser, M., Lu, B., Yang, Z., Strande, V., Begue, D., Zamponi, R., Qiu, S., Sigoillot, F., et al. (2019) · eLife · doi:10.7554/elife.50223 · Cited by 57
Li, S., Liu, Z., Zhu, F., Fan, X., Wu, X., Zhao, H., & Jiang, L. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13832473330032 · Cited by 57
CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma
Teodorczyk, M., Kleber, S., Wollny, D., Sefrin, J. P., Aykut, B., Mateos, Á., Herhaus, P., Sancho-Martinez, I., Hill, O., Gieffers, C., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2014.217 · Cited by 55
Fan, P., Narzisi, G., Jayaprakash, A. D., Venturini, E., Robine, N., Smibert, P., Germer, S., Yu, H. A., Jordan, E., Paik, P. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717782115 · Cited by 56
CD95-mediated cell signaling in cancer: mutations and post-translational modulations
Tauzin, S., Debure, L., Moreau, J., & Legembre, P. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0866-4 · Cited by 60
Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D. A., Rakiec, D. P., Korn, J. M., McAllister, G., Stegmeier, F. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 56
Jeong, S.-C., Cho, Y., Song, M., Lee, E., & Ryu, J. (2017) · Environmental Toxicology · doi:10.1002/tox.22390 · Cited by 55
Xia, Y., Wang, W., Shen, W., Xu, K., Hu, Y., Han, G., & Liu, Y.-B. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109652 · Cited by 53
Fan, X., Li, N., Wu, J., Zhou, Y., He, J., Liu, L., & Leung, E. L. (2014) · Molecules · doi:10.3390/molecules19033508 · Cited by 53
EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells
De, S., Dermawan, J. K. T., & Stark, G. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412390111 · Cited by 53
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Salmón, M., Álvarez-Díaz, R., Fustero-Torre, C., Brehey, O., Lechuga, C. G., Sanclemente, M., Fernández-García, F., López-García, A., Martín-Guijarro, M. C., Rodríguez-Perales, S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164413 · Cited by 52
Yu, W., Lü, W., Chen, G., Cheng, F., Su, H., Chen, Y., Liu, M., & Pang, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13961 · Cited by 52
Rotolo, R., Leuci, V., Donini, C., Cykowska, A., Gammaitoni, L., Medico, G., Valabrega, G., Aglietta, M., & Sangiolo, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112839 · Cited by 53
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
ERBB oncogene proteins as targets for monoclonal antibodies
Polanovsky, O. L., Lebedenko, E. N., & Deyev, S. M. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912030029 · Cited by 49
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Jotte, R. M., & Spigel, D. R. (2015) · Cancer Medicine · doi:10.1002/cam4.506 · Cited by 51
Minnelide: A Novel Therapeutic That Promotes Apoptosis in Non-Small Cell Lung Carcinoma In Vivo
Roušalová, I., Banerjee, S., Sangwan, V., Evenson, K., McCauley, J. A., Kratzke, R. A., Vickers, S. M., Saluja, A. K., & D’Cunha, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077411 · Cited by 48
Bonavida, B. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014011929 · Cited by 48
Nakade, J., Takeuchi, S., Nakagawa, T., Ishikawa, D., Sano, T., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000170 · Cited by 48
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
Ibusuki, R., Iwama, E., Shimauchi, A., Tsutsumi, H., Yoneshima, Y., Tanaka, K., & Okamoto, I. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00557-2 · Cited by 48
S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB
Feng, P., Yu, C.-T., Chen, K.-Y., Luo, C.-S., Wu, S. M., Liu, C., Kuo, L.-W., Chan, Y., Chen, T.-T., Chang, C.-C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24146 · Cited by 46
Liu, Y., Tsai, M., Wu, S., Chang, T., Tsai, T.-H., Gow, C., Wang, H., & Shih, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.09.015 · Cited by 46
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Rosell, R., Cardona, A. F., Arrieta, O. G., Aguilar, A., Ito, M., Pedraz‐Valdunciel, C., Codony‐Servat, J., & Santarpía, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01519-2 · Cited by 48
Self-citationGenetic modifiers of EGFR dependence in non-small cell lung cancer
Sharifnia, T., Rusu, V., Piccioni, F., Bagul, M., Imielinski, M. B., Cherniack, A. D., Pedamallu, C. S., Wong, B., Wilson, F. H., Garraway, L. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412228112 · Cited by 48
Kusne, Y. N., Silva, E. A. C., Perry, A. S., Rushing, E. J., Mandell, E. K., Dietrich, J. D., Errasti, A. E., Gibbs, D., Berens, M. E., Loftus, J. C., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005196 · Cited by 44
Sesumi, Y., Suda, K., Mizuuchi, H., Kobayashi, Y., Sato, K., Chiba, M., Shimoji, M., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.12.012 · Cited by 44
Stuhlmiller, T. J., Zawistowski, J. S., Chen, X., Sciaky, N., Angus, S. P., Hicks, S. T., Parry, T. L., Huang, W., Beak, J. Y., Willis, M. S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006635 · Cited by 44
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression
Tang, X., Jin, L., Cao, P., Cao, K., Huang, C., Luo, Y., Ma, J., Shen, S., Tan, M., Li, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8056 · Cited by 43
Drug-adapted cancer cell lines as preclinical models of acquired resistance
Michaelis, M., Wass, M. N., & Cinatl, J. J. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.005 · Cited by 47
Zhao, Y., Wang, H., & He, C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03828-8 · Cited by 45
Japonicone A Suppresses Growth of Burkitt Lymphoma Cells through Its Effect on NF-κB
Li, X., Yang, X., Liu, Y., Gong, N., Yao, W., Chen, P., Qin, J., Jin, H., Li, J., Chu, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3258 · Cited by 42
Majem, M., & Remón, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.09 · Cited by 41
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
Lazzari, C., Spreafico, A., Bachi, A., Röder, H., Floriani, I., Garavaglia, D., Cattaneo, A., Grigorieva, J., Viganò, M. G., Sorlini, C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f17 · Cited by 40
NF-kappaB in Lung Tumorigenesis
Cai, Z., Tchou-Wong, K.-M., & Rom, W. N. (2011) · Cancers · doi:10.3390/cancers3044258 · Cited by 40
IκB Kinase α Is Required for Development and Progression of KRAS -Mutant Lung Adenocarcinoma
Vreka, M., Lilis, I., Papageorgopoulou, M., Giotopoulou, G. A., Lianou, M., Giopanou, I., Kanellakis, N. I., Σπέλλα, Μ., Agalioti, T., Armenis, V., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1944 · Cited by 40
Kang, Y., Hu, W., Bai, E., Zheng, H., Liu, Z., Wu, J., Jin, R., Zhao, C., & Liang, G. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s118272 · Cited by 39
Yamauchi, Y., Izumi, Y., Yamamoto, J., & Nomori, H. (2013) · Phytotherapy Research · doi:10.1002/ptr.5056 · Cited by 39
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.
Luo, M., & Fu, L.-W. (2014) · Europe PMC (PubMed Central) · Cited by 38
Liang, J., Bi, G., Sui, Q., Zhao, G., Zhang, H., Bian, Y., Chen, Z., Huang, Y., Xi, J., Shi, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113771 · Cited by 38
Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Ariyawutyakorn, W., Saichaemchan, S., & Varella‐Garcia, M. (2016) · Journal of Cancer · doi:10.7150/jca.12663 · Cited by 37
Strezoska, Ž., Licon, A., Haimes, J. D., Spayd, K. J., Patel, K. M., Sullivan, K., Jastrzebski, K., Simpson, K. J., Leake, D., Smith, A. V. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042341 · Cited by 38
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Wood, K. C., Konieczkowski, D. J., Johannessen, C. M., Boehm, J. S., Tamayo, P., Botvinnik, O. B., Mesirov, J. P., Hahn, W. C., Root, D. E., Garraway, L. A., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002612 · Cited by 36
Pharmacogenetics of EGFR in Lung Cancer: Perspectives and Clinical Applications
Mayo, C., Bertrán-Alamillo, J., Molina‐Vila, M. Á., Giménez-Capitán, A. A., Costa, C., & Rosell, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.54 · Cited by 36
Self-citationLi, W., Wang, H., Yang, Y. F., Zhao, T., Zhang, Z., Tian, Y., Shi, Z., Peng, X., Li, F., Feng, Y., et al. (2018) · PROTEOMICS · doi:10.1002/pmic.201700388 · Cited by 38
Jönsson, V. D., Blakely, C. M., Lin, L., Asthana, S., Matni, N., Olivas, V. R., Pazarentzos, E., Gubens, M. A., Bastian, B. C., Taylor, B. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44206 · Cited by 36
Self-citationSystemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Karachaliou, N., Rosell, R., Morales-Espinosa, D., & Viteri, S. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.896210 · Cited by 35
Self-citationSynthetic lethality in lung cancer and translation to clinical therapies
Leung, A. W. Y., de Silva, T., Bally, M. B., & Lockwood, W. W. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0546-y · Cited by 35
Ta, N. L., Chakrabandhu, K., Huault, S., & Hueber, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-30804-z · Cited by 37
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
Self-citationBalta, G. S. G., Monzel, C., Kleber, S., Beaudouin, J., Balta, E., Kaindl, T., Chen, S., Gao, L., Thiemann, M., Wirtz, C. R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.054 · Cited by 35
Entezari, M., Abad, G. G. Y., Sedghi, B., Ettehadi, R., Asadi, S., Beiranvand, R., Haratian, N., Karimian, S. S., Jebali, A., Khorrami, R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115673 · Cited by 35
FBXW 7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy
Xiao, Y., Yin, C., Wang, Y., Lv, H., Wang, W., Huang, Y., Pérez‐Losada, J., Snijders, A. M., Mao, J., & Zhang, P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12200 · Cited by 34
mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF
Ishikawa, D., Takeuchi, S., Nakagawa, T., Sano, T., Nakade, J., Nanjo, S., Yamada, T., Ebi, H., Zhao, L., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062104 · Cited by 33
Overexpression of CARMA3 in Non-Small-Cell Lung Cancer Is Linked for Tumor Progression
Li, Z., Qu, L., Dong, Q., Huang, B., Li, H., Tang, Z., Xu, Y., Luo, W., Liu, L., Qiu, X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036903 · Cited by 33
Suda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
Zhang, S., Chen, Z., Shi, P., Fan, S., He, Y., Wang, Q., Li, Y., Ramalingam, S. S., Owonikoko, T. K., & Sun, S. (2021) · Theranostics · doi:10.7150/thno.54824 · Cited by 33
Hamed, M. M., Darwish, S. S., Herrmann, J. E., Abadi, A., & Engel, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01774 · Cited by 33
Hypoxia and aging: molecular mechanisms, diseases, and therapeutic targets
Nisar, A., Khan, S., Li, W., Hu, L., Samarawickrama, P. N., Gold, N. M., Zi, M., Mehmood, S. A., Miao, J., & He, Y. (2024) · MedComm · doi:10.1002/mco2.786 · Cited by 33
Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822eeba2 · Cited by 32
The new concepts on overcoming drug resistance in lung cancer
Dong, X., Xu, C., Lei, P., & Zhang, W. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s60672 · Cited by 32
Jiang, L., Zhang, W., Li, W., Ling, C., & Jiang, M. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.10.013 · Cited by 33
Ho, J.-Y., Lu, H., Cheng, H.-H., Kuo, Y.-C., Lee, Y.-L. A., & Cheng, C. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00639-4 · Cited by 32
A primer on using pooled shRNA libraries for functional genomic screens
Hu, G., & Luo, J. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr116 · Cited by 35
Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194693 · Cited by 31
Nishihara, S., Yamaoka, T., Ishikawa, F., Higuchi, K., Hasebe, Y., Manabe, R., Kishino, Y., Kusumoto, S., Andō, K., Kuroda, Y., et al. (2022) · Genes · doi:10.3390/genes13122183 · Cited by 34
Kim, G. W., Song, J. S., Choi, C., Rho, J. K., Kim, S. Y., Jang, S. J., Park, Y. S., Chun, S., Kim, W. S., Lee, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.023 · Cited by 31
Rossi, A., Pasquale, R., Esposito, C., & Normanno, N. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.09.001 · Cited by 31
Metadata
- Authors
- Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., Hannon, G., & Sawyers, C. L.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Cold Spring Harbor Laboratory (US)
- Institut Català d'Oncologia (ES)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Sawyers, Charles L.
- ORCID
- Venue
- Nature
- Published
- 2011-03
- Volume
- 471
- Issue
- 7339
- Pages
- 523-526
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3541675
- OpenAlex
- W2087955215
- Cited by
- 396
- References
- 24
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 14 · 2022: 20 · 2021: 19 · 2020: 17 · 2019: 33 · 2018: 46 · 2017: 38 · 2016: 25 · 2015: 27 · 2014: 37 · 2013: 37 · 2012: 39
- FWCI
- 37.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Memorial Sloan-Kettering Cancer Center
- National Cancer Institute (P01CA013106)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- NF-κB signaling, erlotinib, EGFR tyrosine kinase inhibitors, drug resistance, IκB, c-FLIP, IκB kinase, RNAi screen, lung adenocarcinoma, apoptosis, combination therapy, treatment response biomarkers, non-smoker lung cancer
- MeSH terms
- Erlotinib Hydrochloride, Dose-Response Relationship, Drug, Humans, Lung Neoplasms, Models, Biological, Mutation, Quinazolines, Signal Transduction, Down-Regulation, NF-kappa B, Genes, erbB-1, Drug Resistance, Neoplasm, fas Receptor, I-kappa B Proteins, RNA Interference, Cell Line, Tumor, Mutant Proteins, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
